Shares of Rocket Pharmaceuticals surged 10.1% to $2.79 on October 8 after Goldman Sachs upgraded the stock from Sell to Neutral and raised its price target from $3 to $4, a move driven by updated clinical data for the company's gene therapy targeting Danon disease — a rare, life-threatening heart condition. The upgrade offers a lifeline of credibility for a stock that has lost the vast majority of its value, but the core question remains: can this company fund itself long enough to reach a pivotal data readout still two years away? Goldman Upgrades Rocket Pharmaceuticals to Neutral, but With Pivotal Data Two Years Away, Is $2.79 a Bet or a Bargain?
Shares of Rocket Pharmaceuticals jumped 10.1% to $2.79 after Goldman Sachs upgraded the gene therapy maker from Sell to Neutral and raised its price target from $3 to $4. The catalyst: updated data from the company's experimental heart therapy for Danon disease — a rare genetic condition that causes fatal heart failure in young men. But with pivotal trial results not expected until 2028, investors must decide whether this is a meaningful inflection point or simply a longer leash on a high-risk bet.
A Wall Street Upgrade That Still Doesn't Say "Buy" Goldman's move is modest. A Neutral rating means the bank sees limited near-term upside beyond its $4 target — roughly 43% above today's price but still a fraction of the stock's 52-week high of $5.45. Jefferies holds a "hold" rating with a $2.95 target , while Chardan Capital maintains a "buy" at $11 and Needham recently upgraded to "buy" at $9 . The analyst community is deeply split, reflecting genuine uncertainty about whether this therapy will ever reach market.
The Data That Changed Goldman's Mind
An October 6 investor webinar outlined sustained biological activity in longer-term Phase 1 follow-up and encouraging initial safety observations in the first three patients treated under the modified protocol. Critically, trial success requires at least 7 of 12 patients to show meaningful protein expression in heart tissue and a 10% reduction in a key cardiac measurement at 12 months — thresholds intended to support accelerated FDA approval.
No evidence of dangerous blood-clotting or fluid-leak side effects was observed , a relief given an earlier clinical hold that paused the trial in 2025.
Cash Runway Covers the Wait — Barely Rocket has been aggressively shoring up its balance sheet. In April, the company sold a regulatory voucher for $180 million in non-dilutive capital.
On October 6 it announced a $150 million credit facility from Hercules Capital, with an initial $35 million draw, extending its cash runway into Q3 2028.
As of June 30, Rocket held $283.7 million in cash and investments. That runway roughly aligns with the pivotal data timeline — leaving almost no margin for delays.
A Sub-$300 Million Company Carrying Enormous Binary Risk
Rocket's market capitalization was just $270.8 million as of October 6 , meaning the entire company is valued at less than its cash pile. That signals the market prices in significant probability of failure. Danon disease affects an estimated 15,000 to 30,000 patients in the U.S. and Europe , a potentially lucrative niche — if the therapy works. Until 2028, RCKT remains a waiting game where the science, not the stock chart, will write the ending.